Bioventus Inc.
BVSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Bioventus Inc. (BVS) is listed under Medical Devices. The company carries a $961.1M market cap, placing it firmly in the small-cap category. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Market Cap
$961.1M
Beta
0.65
P/E (TTM)
18.04
P/E (Fwd)
15.29
EPS (TTM)
$0.78
EPS (Fwd)
$0.92
ROE
25.7%
ROA
5.5%
Cash
$30.4M
Total Debt
$263.7M
Free CF
$67.8M
52W Change
93.5%
Annual Financials
Cash vs Debt
Where BVS stands vs its 150-day and 200-day moving averages
As of the August 17, 2026 close, BVS finished 45.66% above its 150-day moving average ($9.79) and 55.17% above its 200-day moving average ($9.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BVS overbought or oversold?
At the August 17, 2026 close, BVS's RSI(14) was 67.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BVS has $30.4M in cash with $263.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $67.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 25.7%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $512.1M to $568.1M.
The relatively low beta of 0.65 suggests BVS is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bioventus Inc. and its sector.